Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE